Agilent Announces New SureSelect Human All Exon V8
June 02 2021 - 8:00AM
Business Wire
Design provides comprehensive content and flexible exome
options
Agilent Technologies Inc. (NYSE: A) today announced the release
of SureSelect Human All Exon V8 – a new exome design that provides
comprehensive content and up-to-date coverage of protein coding
regions from RefSeq, CCDS, and GENCODE. It also covers the TERT
promoter and hard-to-capture exons that are omitted by other exomes
on the market. The new design is available in three options –
routine exome sequencing (Exome v8), clinical research sequencing
(v8 Clinical Plus), and translational research (v8 UTR Plus) –
allowing for content flexibility to meet our customer’s needs.
Powered by machine learning-based probe design and an improved
probe-printing process, the SureSelect Human All Exon V8 spans a
35.1 Mb target region of the human genome, with an efficient
end-to-end design size of only 41.6 Mb. The panel delivers
excellent enrichment performance for more uniform coverage, as well
as efficient and cost-effective exome sequencing.
Kevin Meldrum, vice president and general manager for Agilent's
Genomics Division, discussed the impact of the release. “The
SureSelect exome has been widely adopted in both clinical and
translational research, and it has played an important role in
shaping the rise of exome sequencing as a routine genomics
technique," he said. "The SureSelect Human All Exon V8 provides
best-in-class enrichment performance and sequencing efficiency, and
it shows our commitment to exceed customer expectations and
continue our legacy as the benchmark exome to the genomics
community."
This new exome design is already delivering promising results in
genetics by supporting virtual analysis of targeted genes important
in germline investigations through seamless integration with Alissa
Interpret for variant interpretation and reporting. In cancer,
exome sequencing is commonly used to identify mutations that
contribute to tumor progression, and the sequencing efficiency and
coverage achieved with this new design will enable customers to get
more out of each exome capture than ever before to identify
critical genomic targets. In addition, large-scale manufacturing
ensures the panel will provide consistent results for many years,
another critical need in clinical research laboratories.
These new Exome designs can be automated on the Bravo automated
liquid handling platform for high throughput applications and the
Magnis NGS Prep System for complete, walkaway automation. The
complete, pushbutton automation provided by the Magnis system will
allow laboratories to efficiently deploy exome sequencing while
reducing labor and operational expenses.
About Agilent Technologies
Agilent is a leader in life sciences, diagnostics, and applied
chemical markets, delivering innovative technology solutions that
provide trusted answers to researchers’ most challenging scientific
questions. The company generated revenue of $5.34 billion in fiscal
year 2020 and employs 16,400 people worldwide. Information about
Agilent is available at www.agilent.com. To receive the latest
Agilent news, please subscribe to the Agilent Newsroom. Follow
Agilent on LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210602005348/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024